



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 46221

In re patent application of  
SASAKI et al.  
Serial No. 09/869,185  
Filed: June 25, 2001  
For: METHOD OF BREEDING YEAST

Group Art Unit: 1636  
Examiner: B. Loeb

RECEIVED  
MAR 03 2003  
TECH CENTER 1600/2900

TRANSMITTAL OF RESPONSE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


Transmitted herewith is an Response in the above-captioned application. The fee has been calculated as shown below. (*Small entity fees indicated in parentheses.*)

CLAIMS AS AMENDED							
(1)	(2)	(3)	(4)	(5)	(6)	(7)	
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee	
Total Claims	8	-	20		18.00	\$0	
(Small Entity)					(9.00)		
Independent claims	4	-	4		84.00	\$0	
(Small Entity)					(42.00)		
Multiple Dependent	0	-	0	0	280.00	0	
(Small Entity)					(140.00)		
Extension of Time	One Month		Two Months	Three Months			
Fee	\$110		\$410	\$930		\$0	
(Small Entity)	(\$55)		(\$205)	(\$465)		0	
Total							\$0


The above fees are believed to be correct. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0687 under the above Attorney Docket Number for which purpose this paper is submitted in duplicate.

Respectfully submitted,

Date: February 26, 2003

  
Paul E. White, Jr.  
Reg. No. 32,011  
Tel. No. 202-261-1050  
Fax No. 202-887-0336

Manelli Denison & Selter, PLLC  
2000 M Street, N.W.  
Suite 700  
Washington, D.C. 20036-3307  
202.261.1000



## Notice to Comply

Application No.

09/869,185

Examiner

Bronwen M. Loeb

Applicant(s)

ASHIKARI ET AL.

Art Unit

1636

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:

#### Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance..... 703-287-0200

To Purchase PatentIn Software..... 703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

RECEIVED

MAR 03 2003

TECH CENTER 1800,2900